NOW AVAILABLE • SHIPPING WITHIN 1-3 BUSINESS DAYS

Your cart

Your cart is empty

Continue shopping

Ozempic Face: What It Is, Why It Happens, and What Actually Helps

DermaReverse serum, the topical evaluated in a placebo-controlled, split-face clinical study in GLP-1 users

"Ozempic face" is an informal, non-medical nickname for the visible facial changes some people notice during or after substantial weight loss, including weight loss on GLP-1 medications such as Ozempic®, Wegovy®, Zepbound®, and Mounjaro®: reduced fullness, a hollow or deflated look, and skin that appears looser, drier, or more lined. Rapid facial fat loss is the best-established explanation. Researchers are also examining whether GLP-1 therapy may be associated with changes in the quality of the skin itself. The science is still evolving, but there are practical, evidence-based ways to support how your skin looks throughout the journey. This page explains what the term means, why it happens, whether it fades, what helps, and what the research actually shows.

Written by Alec Semersky, Aforé's co-founder and formulator, and first author of the first placebo-controlled, split-face clinical study of a topical skincare solution designed and tested in GLP-1 users in a published peer reviewed medical journal. See the research ↓

What people mean by "Ozempic face"

The phrase spread as semaglutide and the dual GIP/GLP-1 medication tirzepatide became common in diabetes care and weight management. Approved indications vary by product. "Ozempic face" is media shorthand, not a medical diagnosis, and facial aging or facial volume loss is not identified as an adverse reaction in current FDA-approved Ozempic prescribing information.8 The term generally describes a cluster of visible changes that may accompany substantial or rapid weight loss:

  • A flatter or more "deflated" look in the cheeks
  • More prominent bone structure and hollowing under the eyes
  • Skin that appears looser along the jawline and neck
  • Fine lines and folds that look more noticeable
  • Drier, duller, or rougher-looking skin
  • An overall tired or gaunt appearance

Some people prefer "GLP face" or "GLP-1 face," since the same changes are reported across the medication class, and across rapid weight loss by any method.

Why it happens

Several factors may contribute, and they can overlap.

Rapid fat loss

Facial fat gives the skin underlying volume. The face contains fat compartments that contribute to a smooth, full appearance, and when they shrink quickly, the overlying skin can look deflated, looser, or more lined because there is less fullness beneath it.

Skin may take time to adjust

Collagen and elastin help give skin its firm, resilient appearance. Their natural levels decline with age, and after substantial or rapid weight loss the skin may not visibly adjust to smaller facial contours at the same pace, making lines or laxity look more noticeable.

Changes in muscle and underlying support

Weight loss can include both fat and lean mass. Because muscle contributes to the underlying support of the face and body, clinicians often discuss adequate protein intake and resistance training as part of a medically supervised weight-management plan.

Emerging research: the quality of the skin itself

Researchers are examining whether GLP-1-based medications may influence skin biology in addition to producing weight loss. A 2024 review in Aesthetic Surgery Journal described GLP-1-related facial changes as potentially multifactorial, involving loss of dermal and subcutaneous fat, altered activity of adipose-derived stem cells, and downstream effects on the skin's supportive environment.1 GLP-1 is a signaling molecule with activity throughout the body,2 and laboratory and clinical research has shown that GLP-1 receptor agonists can act on keratinocytes and influence inflammatory signaling and wound-healing pathways.3,4 GLP-1 therapy has also been studied in connection with inflammatory skin conditions such as psoriasis.5 Broader safety literature continues to examine effects associated with this medication class.6

This evidence provides a scientific basis for continued research, but it does not yet establish that GLP-1 medications directly cause changes in human facial skin independent of weight loss. It is important to distinguish emerging biological theories from proven causation. Nutrition may also play a supporting role: healthy skin renewal depends on adequate intake of nutrients including vitamin A and other micronutrients,7 and appetite, food intake, and hydration can all change during GLP-1 treatment. Individual nutrition needs are best discussed with a prescribing clinician or registered dietitian.

When does Ozempic face start?

There is no fixed timeline, and the experience varies from person to person. In general, visible facial changes track with the pace and amount of weight loss: the faster or greater the loss, the more noticeable the change may be. Some people begin to notice differences within the first several months as fat reduction becomes visible in the face; others notice little or no change. If you are concerned about the pace of weight loss, speak with your prescribing clinician. Do not change your medication, dose, or schedule to address a cosmetic concern without medical guidance.

Does it go away? Is it permanent?

There is not enough long-term clinical evidence to predict how often these changes improve after weight stabilizes. What happens over time depends on several factors:

  • Age and skin elasticity. Skin with greater natural elasticity may adapt more readily to changing contours.
  • How fast and how much weight was lost. Larger or faster changes can make volume loss and laxity more visible.
  • Time at a stable weight. Appearance may continue to evolve after weight loss slows or stabilizes.
  • The type of change. Lost facial volume, surface dehydration, visible lines, and skin laxity are different concerns and respond to different approaches.

Some visible changes may soften as weight stabilizes, while others may persist. We go deeper in Does Ozempic Face Go Away?

The distinction that decides what helps: skin quality vs. volume vs. laxity

When someone says their face "looks different" or their skin is "sagging," they are usually noticing one of three things, or a combination, and each responds differently.

  • Skin quality is how skin looks and feels overall: hydration, firmness, texture, smoothness, radiance, tone, pores, and fine lines. This is where a consistent topical routine is most relevant.
  • Volume is fullness beneath the skin. Topical skincare cannot replace lost facial volume. Volume concerns are a conversation for a qualified aesthetic provider.
  • Laxity is looseness or reduced support in the skin or underlying tissue. Mild laxity overlaps with skin quality; deeper laxity is best evaluated by a provider.

Knowing which of the three you are seeing is the key to knowing what will actually help. Our GLP-1 skin glossary defines each of the terms above in plain English.

Who is most likely to notice it?

You may be more likely to see noticeable facial changes if you are losing weight quickly or have lost a substantial amount, are older (skin elasticity naturally decreases with age), have had significant sun exposure over time, or started with more facial fullness that is now decreasing. None of these factors guarantees a change. Individual experiences vary, and the changes described by the term are cosmetic rather than a medical diagnosis.

Ozempic face vs. normal aging

The visible changes overlap, which is why they can be hard to tell apart. Age-related loss of facial volume and skin quality typically develops gradually over years. Changes noticed during a GLP-1 journey may appear more quickly and often track with the pace of weight loss. In practice the concerns look similar, less fullness, more noticeable lines, skin that appears less firm, and many of the appearance-supporting approaches overlap.

What actually helps

Options range from everyday habits and consistent skincare to professional procedures. The right approach depends on whether the primary concern is volume, skin quality, or both.

Support your body from the inside

  • Discuss a healthy rate of weight loss with your clinician. Never change your medication, dose, or schedule for a cosmetic concern without speaking with your prescriber.
  • Prioritize adequate protein. Protein supports the maintenance of muscle and other tissues. A clinician or registered dietitian can help determine what is appropriate for you.
  • Consider resistance training when medically appropriate; it helps support muscle during weight loss.
  • Pay attention to hydration. Some people eat or drink less during treatment, and gastrointestinal side effects can contribute to dehydration.8
  • Protect against sun exposure. Daily broad-spectrum SPF is one of the most consistently recommended steps for maintaining the appearance of skin quality over time.

Support your skin's appearance with a consistent routine

A steady skincare routine cannot change your weight or replace lost facial volume, but appearance-supporting ingredients can help skin look firmer, smoother, and more hydrated:

  • Peptides support the look of firmness
  • Hyaluronic acid supports a hydrated, plumper-looking surface
  • Retinol and other cosmetic vitamin A derivatives support the appearance of smoother texture and fewer visible fine lines
  • Antioxidants such as vitamin C support a brighter, more even-looking complexion

For a simple morning and night structure, see our GLP-1 skincare routine guide.

Professional options

For more pronounced changes, some people consult a board-certified dermatologist or plastic surgeon about in-office options. These are medical procedures performed by licensed providers, not skincare, and may include injectable fillers to restore volume, energy-based skin-tightening procedures, microneedling, or, for significant loose skin, surgical options. A qualified provider can assess whether any of these is appropriate for you. Our guide to skincare versus in-office treatments explains where each fits.

What the research actually shows

Most skincare marketed to GLP-1 users is general-purpose skincare with a new label. Claims are typically supported by consumer perception surveys, by studies of a single active ingredient rather than the finished formula, or by results that are summarized but never published in full. Very few cosmetic brands run IRB-approved clinical studies. Fewer publish in a medical journal. Fewer still pass peer review and publish the complete results open access, where anyone can read and check them.

DermaReverse was evaluated in a study that meets all of those standards: a single-center, blinded, placebo-controlled, split-face clinical study in women using GLP-1 receptor agonist or SGLT-2 therapy, published open access in Aesthetic Surgery Journal Open Forum in 2025, with Alec Semersky as first and corresponding author.9

Study participant's lower face at Day 1, baseline, before DermaReverse use
Day 1 · Baseline
Study participant's lower face at Day 42, after six weeks of twice-daily DermaReverse use
Day 42 · After six weeks

Photographs are of a single study participant and have not been retouched. Individual results may vary.

The study at a glance

  • Design: placebo-controlled, blinded, split-face. Each participant applied DermaReverse to one side of the face and a placebo to the other, twice daily for six weeks, so every participant served as her own control.
  • Population: a pilot group of seven women, ages 34 to 64 (median 55), all using GLP-1 or SGLT-2 therapy, all with visible skin-quality concerns, maintaining a stable weight during the study.
  • What was measured: 13 visible skin-quality parameters on the Global Ranking Scale, including elasticity, surface roughness, dehydration, static and dynamic wrinkles, volume loss, sagging, pores, pigmentation, and vasculature, assessed at baseline, Day 21, and Day 42.
  • Result: the DermaReverse-treated side showed statistically significant improvement compared with the placebo side across the measured parameters, with visible improvement by Day 21 and additional improvement by Day 42.
  • Safety: no adverse events were reported.
  • Publication: peer-reviewed, open access. Read the full paper or see our plain-English summary of the clinical study.

A note on scale: this was a pilot study, and a split-face design is unusually informative per participant precisely because it removes person-to-person variation, but it is one study. It evaluated DermaReverse's cosmetic effects in GLP-1 users; it was not designed to determine what caused participants' underlying skin concerns, and individual results vary. Aforé sponsored the study. We publish these details because we think you should be able to judge the evidence for yourself.

Your questions, answered

Each of these guides answers one specific question in depth.

Where DermaReverse fits

Aforé developed DermaReverse specifically for people experiencing visible skin-quality changes during or after a GLP-1 journey, rather than adapting a general anti-aging product. It is a twice-daily cosmetic serum designed to support the appearance of firmness, smoothness, hydration, and overall skin quality, and it is the formula evaluated in the study above. It is a topical skincare product, not a drug, and not a replacement for lost facial volume, in-office treatments, or medical care.

Explore DermaReverse · Read the clinical study summary

About the author

Alec Semersky is CEO, co-founder, and formulator of Aforé. He is first and corresponding author of the 2025 placebo-controlled, split-face clinical study of DermaReverse in GLP-1 users, and co-author of six further medical journal publications in skincare and aesthetic medicine dating to 2016. Read more about Alec or see all seven publications.

Frequently asked questions

Is Ozempic face caused by the medication?

That has not been established. Substantial or rapid weight loss can reduce facial fat and make skin look looser or more lined, whether the weight loss occurs with GLP-1 therapy or through another method. Emerging research is exploring whether GLP-1-based medications may also influence skin biology, but direct effects on human facial skin independent of weight loss have not been proven.

Will Ozempic face go away on its own?

There is limited long-term evidence, and experiences vary. Some visible changes may soften after weight stabilizes, while lost facial volume or more pronounced laxity may persist. Skincare can support the appearance of firmness, smoothness, and hydration, but it cannot replace lost facial volume.

Can skincare fix Ozempic face?

Skincare cannot change your weight or replace lost facial volume. It can support visible skin quality. Appearance-supporting ingredients such as peptides, hyaluronic acid, retinol, and antioxidants can help skin look firmer, smoother, and more hydrated as part of a consistent routine. DermaReverse was the first topical skin solution designed for GLP-1 users to be the subject of a peer-reviewed, medical-journal-published study.

How can I reduce visible facial changes while losing weight?

No approach can guarantee prevention. Common supportive steps include discussing an appropriate rate of weight loss with your clinician, consuming adequate protein, resistance training when medically appropriate, staying hydrated, daily sun protection, and a consistent skincare routine. Do not change your medication or dose without speaking with your prescriber.

Is Ozempic face permanent?

Not necessarily, but there is not enough long-term evidence to predict an individual outcome. Age, skin elasticity, the amount and pace of weight loss, and whether the primary concern is volume or skin quality all influence how the appearance evolves.

Does the same thing happen with Wegovy, Zepbound, or Mounjaro?

The visible changes people describe as "Ozempic face" are associated with substantial or rapid weight loss rather than with one brand. Similar changes are reported across GLP-1 and GIP/GLP-1 medications and across rapid weight loss by any method.

References

  1. Ridha Z, Fabi SG, Zubair R, Dayan SH. Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging. Aesthetic Surgery Journal. 2024;44(11):NP809–NP818. doi:10.1093/asj/sjae132
  2. Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiological Reviews. 2007;87(4):1409–1439. doi:10.1152/physrev.00034.2006
  3. Yang J, Wang Z, Zhang X. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Experimental and Molecular Pathology. 2019;107:124–128. doi:10.1016/j.yexmp.2019.01.014
  4. Nagae K, Uchi H, Morino-Koga S, et al. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes. Diabetes Research and Clinical Practice. 2018;146:155–161. doi:10.1016/j.diabres.2018.10.013
  5. Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Research and Clinical Practice. 2019;150:167–173. doi:10.1016/j.diabres.2019.03.002
  6. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Review of Diabetic Studies. 2014;11(3-4):202–230. doi:10.1900/RDS.2014.11.202
  7. VanBuren CA, Everts HB. Vitamin A in Skin and Hair: An Update. Nutrients. 2022;14(14):2952. doi:10.3390/nu14142952
  8. U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. Revised May 2026. FDA prescribing information
  9. Semersky A, Pryor S, Barwood-Parent C, Lee M, Copeland K, Few J. A Single-Center, Blinded, Placebo-Controlled Study Evaluating Cosmetic Efficacy and Safety of a Novel Topical GLPSGLT in Glucagon-Like Peptide-1 Analog-Treated Patients. Aesthetic Surgery Journal Open Forum. 2025;7:ojaf030. doi:10.1093/asjof/ojaf030

Disclaimer: Aforé and DermaReverse are independent and are not affiliated with, endorsed by, sponsored by, or connected to the makers of any GLP-1 medication. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S, and Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Aforé claims no ownership of these marks; they are used here only to identify the medications discussed. All other trademarks are the property of their respective owners. "Ozempic face" is an informal, non-medical term and is not a diagnosis. This page discusses cosmetic, appearance-level changes in facial volume and skin quality; it does not establish that any medication causes a disease, medical condition, or specific cosmetic change. References to scientific research are provided for general educational context and include an emerging and evolving area of study. Aforé is a cosmetic skincare company; this content is not medical advice and is not a substitute for consultation with a qualified healthcare provider. Do not change any medication, dose, or treatment plan without speaking with your prescribing clinician. None of Aforé's products are intended to diagnose, treat, cure, or prevent any disease. Individual results vary.